The associate professor of neurology at Mayo Clinic Rochester discussed specific findings from a simultaneous comparison of migraine medications in which certain treatments and classes were more effective. [WATCH TIME: 3 minutes]
The director of the Alzheimer’s Disease Research Center at Mayo Clinic detailed the current issues with access and affordability to critical biomarkers in the screening and monitoring of patients in Alzheimer disease trials. [WATCH TIME: 3 minutes]
Leaders of the CMSC Working Group on MRI protocols and clinical guidelines express the need for a unified approach to diagnosing and monitoring multiple sclerosis.
Clive Ballard, MD, spoke on the safety data of pimavanserin, which was presented at the 2021 AAIC meeting, held from July 26-30.
The medical director of the UCSF Multiple Sclerosis Center discussed the idea behind remyelination and shared his thoughts on what the best shot at developing a therapy might be.
The director of the Adult Genetic Epilepsy Program at the University of Toronto talked about the critical issues experienced by patients who transition from pediatric to adult care in epilepsy. [WATCH TIME: 9 minutes]
The professor of neurology, neurotherapeutics, and ophthalmology at UT Southwestern discussed the need to better coordinate care between providers when telemedicine is being utilized in headache and migraine care.
The director of the Center for Spinal Cord Injury Research and co-director of the Spinal Cord Injury Model System Center at Kessler Foundation discussed the secondary medical complications of spinal cord injury and how he and colleagues seek to alleviate them.
Both the busy clinician and the overwhelmed patient benefit from a pointed approach to disease management.
Neurology experts discuss where BTKi’s fit in the multiple sclerosis treatment continuum.
The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared how the previous muscarinic agonists have better informed the development of this investigational agent, VU319.
With the physician deficit projected to grow larger within a decade, this global challenge has become a major focus of large organizations and medical societies.
The senior research scientist at Kessler Foundation offered her personal experience in treating spatial neglect in patients with stroke and potential future treatments on the way.
Here's some of what is coming soon to NeurologyLive® this week.
The professor of neurology at Colorado University spoke about the ongoing phase IV trial to determine the safety of DMT discontinuation in MS.
Neuro-oncology fellow Ashley Aaroe recounts her experience at Neurology on the Hill, advocating for important changes in neurology health care.
The neurologist at Banner-University Medicine Neuroscience Institute offered his perspective on data from an open-label safety assessment of cannabidiol (Epidiolex) in the treatment of tuberous sclerosis complex.
Mary Schroth, MD, and Jacqueline Glascock, PhD, of Cure SMA, share their perspectives on the upcoming annual meeting.
The senior research scientist in the Center for Mobility and Rehabilitation Engineering Research at Kessler Foundation spoke to the research being done into the functional implementation of exoskeletons in neurorehabilitation.
The director of Infantile Spasms Program at UCLA Mattel Children’s Hospital discussed why learning more about patients with infantile spasms may lead to further breakthroughs on the origins of autism spectrum disorder.
The medical director of the Hartford healthcare Headache Center in Connecticut discussed the significance of findings from a study assessing migraine during pregnancy. [WATCH TIME: 4 minutes]
The Director of the UCLA Seizure Disorder Center explained the importance of referring patients with seizures to epilepsy centers.
The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center offers takeaways on hyperbaric oxygen therapy.